GlassScriptPhysician profile
Julie Ann E Summer
NPI 1235762543
$1,349.92
in general payments reported to CMS, 2019-2025
22 companies · $16.71 in 2025
The $16.71 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $399 · 2022: $496 · 2023: $397 · 2024: $40.99 · 2025: $16.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $413 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.91 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $324.26 | 2021-2022 | |
| Genzyme Corporation | $194.22 | 2021-2022 | |
| Genentech USA, INC. | $129.52 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $121.48 | 2023 | Rexulti |
| Daiichi Sankyo INC. | $87.74 | 2022-2023 | Injectafer, Enhertu |
| Puma Biotechnology, INC. | $68.53 | 2021 | |
| Mirati Therapeutics, INC. | $61.03 | 2023 | Krazati |
| Glaxosmithkline, LLC. | $49.33 | 2021-2023 | Ojjaara |
| Celgene Corporation | $41.08 | 2023-2024 | Pomalyst, Reblozyl |
| Seagen INC. | $38.08 | 2023 | Tukysa, Adcetris |
| Lilly USA, LLC | $31.43 | 2021 | |
| Eisai INC. | $23.93 | 2024 | |
| Incyte Corporation | $21.69 | 2021 | |
| Medtronic, INC. | $20.58 | 2023 | Osteocool Rf Ablation System |
| G1 Therapeutics, INC. | $20.13 | 2023 | Cosela |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $19.93 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $19.01 | 2022 | |
| Abbvie INC. | $16.71 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.00 | 2023 | Opdualag |
| Pharmacyclics LLC, An Abbvie Company | $15.97 | 2023 | Epkinly, Imbruvica |
| Myovant Sciences INC. | $15.01 | 2021 | |
| Amgen INC. | $14.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Ann Summer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.